- 31 May 2023Portfolio NewsCumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
- 31 May 2023Portfolio NewsViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
- 19 May 2023SV NewsFirst Steps to Treating Dementia May Lie in Related Diseases
- 15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- 18 April 2023Portfolio NewsNitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
- 6 April 2023Portfolio NewsQurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 9 March 2023Portfolio NewsALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
- 9 March 2023Portfolio NewsQurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
- 23 February 2023Portfolio NewsAviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
- 20 February 2023SV NewsImpact funds help fight dementia and antibiotic resistance
- 13 February 2023Portfolio NewsCerevance Expands Series B Financing with Additional $51 Million